麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

美國,Kythera Biopharma,
KYTHERA Biopharmaceuticals主要是將double chins with Bayer的注射療法進行商業(yè)化

KYTHERA is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.

The aesthetics market has grown dramatically in the United States, driven by a large population of consumers looking to minimize and delay signs of aging and improve their general appearance. Leading the growth in the non-surgical aesthetics market are facial injectable products, principally botulinum toxins and dermal fillers, which have solidified their place as the foundation of the aesthetic medicine market. While botulinum toxins and dermal fillers have created a market for non-surgical rejuvenation of the upper and mid-face, however, undesirable submental fat, or double chin, remains an important yet unaddressed aesthetic target for injectable facial treatment.

ATX-101 is an injectable, facial treatment that we are initially developing to reduce unwanted fat under the chin. If approved by applicable regulatory authorities, we believe ATX-101 will be an attractive non-surgical solution for the reduction of submental fat, representing a new product category within the rapidly growing facial aesthetics market.

KYTHERA’s efforts are led by a unique team with significant biotech and aesthetic medicine capabilities. Our management team, with a combined 185 years of biotechnology and aesthetics experience, played a leadership role in securing FDA approval of marquee aesthetic products, such as BOTOX? and JUVEDERM?, and in successfully commercializing established biotechnology products such as Aranesp?, NEUPOGEN? and Neulasta?.